Published on 29 Feb 2024 on Zacks via Yahoo Finance
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -24.14%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.28 per share when it actually produced a loss of $0.30, delivering a surprise of -7.14%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.